Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults

被引：66

作者：

Musher, Daniel M. ^{[1
,2
]}

Manoff, Susan B. ^{[3
]}

McFetridge, Richard D. ^{[3
]}

Liss, Charles ^{[3
]}

Marchese, Rocio D. ^{[3
]}

Raab, Jennifer ^{[4
]}

Rueda, Adriana M. ^{[1
,2
]}

Walker, Monica L. ^{[3
]}

Hoover, Patricia A. ^{[3
]}

机构：

[1] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA

[2] Baylor Coll Med, Houston, TX 77030 USA

[3] Merck Res Labs, N Wales, PA USA

[4] PPD Vaccines & Biol, Wayne, PA USA

来源：

HUMAN VACCINES | 2011年 / 7卷 / 09期

关键词：

pneumococcal polysaccharide vaccine; revaccination; immunogenicity; antibody persistence; PNEUMOVAX (TM) 23; ELDERLY PERSONS; SERUM TREATMENT; CAPSULAR POLYSACCHARIDE; REVACCINATION; PNEUMONIA; INFLUENZA; CONJUGATE; RESPONSES; AGE;

D O I：

10.4161/hv.7.9.15996

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In a study of older adults, first and second doses of 23-valent pneumococcal polysaccharide vaccine (PN23) induced IgG increases for all 8 vaccine serotypes tested. Participants (n = 143, mean age 76 y) were re-enrolled to study antibody levels after 10 y, and safety and immunogenicity of another PN23 dose. Ten years after first or second doses, mean IgG concentrations exceeded vaccine-naive levels for 7 of 8 serotypes tested. Second and third doses administered at this time were generally well tolerated and were immunogenic, inducing similar postvaccination levels. Provided that sufficient time is allowed to elapse after each dose, immunogenicity is preserved after multiple PN23 doses without evidence of a lower than expected immune response (i.e., without hyporesponsiveness).

引用

页码：919 / 928

页数：10

共 32 条

[1]

[Anonymous], 1997, MMWR Recomm Rep, V46, P1

[2] SERUM THERAPY REVISITED - ANIMAL-MODELS OF INFECTION AND DEVELOPMENT OF PASSIVE ANTIBODY THERAPY [J].

CASADEVALL, A ;

SCHARFF, MD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) :1695-1702

[3] Effects of very early serum treatment in pneumococcus type I pneumonia [J].

Cecil, RL .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1937, 108 :689-692

[4] Reactogenicity trends by age to influenza and pneumococcal vaccines [J].

D'Alessandro, D ;

Rossini, A ;

Fara, GM ;

Ciriminna, S .

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (05) :910-911

[5] IMMUNOGENICITY OF PNEUMOCOCCAL REVACCINATION IN PATIENTS WITH CHRONIC DISEASE [J].

DAVIDSON, M ;

BULKOW, LR ;

GRABMAN, J ;

PARKINSON, AJ ;

CHAMBLEE, C ;

WILLIAMS, WW ;

LANIER, AP ;

SCHIFFMAN, G .

ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (19) :2209-2214

[6] The serum treatment of lobar pneumonia [J].

Finland, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1930, 202 :1244-1247

[7] The specific serum treatment of pneumococcus type II Pneumonia [J].

Finland, M ;

Sutliff, WD .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1933, 100 :560-566

[8] The effect of age on immunologic response to recombinant hepatitis B vaccine: A meta-analysis [J].

Fisman, DN ;

Agrawal, D ;

Leder, K .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (11) :1368-1375

[9] Antibody response to influenza vaccination in the elderly: A quantitative review [J].

Goodwin, K ;

Viboud, C ;

Simonsen, L .

VACCINE, 2006, 24 (08) :1159-1169

[10] Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: No evidence of hyporesponsiveness [J].

Hammitt, Laura L. ;

Bulkow, Lisa R. ;

Singleton, Rosalyn J. ;

Nuorti, J. Pekka ;

Hummel, Kim Boyd ;

Miernyk, Karen M. ;

Zanis, Carolyn ;

Whaley, Melissa ;

Romero-Steiner, Sandra ;

Butler, Jay C. ;

Rudolph, Karen ;

Hennessy, Thomas W. .

VACCINE, 2011, 29 (12) :2287-2295

← 1 2 3 4 →